Journal
CRITICAL REVIEWS IN IMMUNOLOGY
Volume 35, Issue 5, Pages 417-432Publisher
BEGELL HOUSE INC
DOI: 10.1615/CritRevImmunol.v35.i5.50
Keywords
Therapy; prognosis; monoclonal antibodies; multiple myeloma; clinical trials; chronic lymphocytic leukemia
Categories
Funding
- Swiss Cancer League [KLS-3189-02-2013]
Ask authors/readers for more resources
CD38 is widely accepted as a marker for unfavorable prognosis in chronic lymphocytic leukemia (CLL). Nevertheless, its direct contribution to the disease pathogenesis is not very well understood. Recent data indicate that CD38 may promote CLL pathogenesis by enhancing proliferation in synergy with B-cell receptor (BCR) signaling and by supporting migration and homing of CLL cells to secondary lymphoid organs, where the malignant cells receive support from the tumor microenvironment. CD38 may also contribute to a suppressed anticancer immune response through the production of tolerogenic compounds. This review first shortly summarizes the biology, expression, and function of CD38 in general and in CLL cells in more detail. Next, the current literature and open questions regarding a direct contribution of CD38 to CLL pathogenesis are critically reviewed. Finally, I discuss the potential of CD38 as therapeutic target in light of its possible roles in CLL and the promising results of clinical trials with CD38 antibodies in multiple myeloma (MM).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available